More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm To Commence Phase 2 Ross River Virus Clinical Trial

Jul 9, 2017 at 10:49 PM EDT · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Jul 9, 2017 at 10:49 PM EDT

On 6ix: 6ix.com/news/paradigm-to-commence-phase-2-ross-river-virus-clinical-trial

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Paradigm Biopharmaceuticals Ltd. on 6ix

Story so far

  • Paradigm Update Ross River Virus Clinical TrialMar 7, 2017
  • Paradigms hay fever clinical trial cleared to commenceNov 22, 2016

Earlier from Paradigm Biopharmaceuticals

  • Paradigm Enters Heart Failure MarketJun 19, 2017
  • Hay Fever Trial UpdateJun 15, 2017
  • Paradigm Receives Ethics Approval for Ross River TrialMay 21, 2017
  • Paradigms preclinical hay fever trial publishedMay 15, 2017
  • Paradigm Government grant for Ross River virus researchMay 10, 2017

Later from Paradigm Biopharmaceuticals

  • Paradigm (PAR) - First Ross River Trial Participant TreatedAug 8, 2017
  • Appendix 4E and 2017 Annual ReportAug 29, 2017
  • A Paradigm shift in treating osteoarthritis painSep 10, 2017
  • Paradigm Phase 2 Ross River Virus Clinical Trial UpdateSep 13, 2017
  • PARs Osteoarthritis Phase 2 Receives Ethics ApprovalSep 18, 2017
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer